CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$270.62M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 1.92: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.14BUSDvs all stocks (USD)
Revenue (TTM)
117.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8120xvs all stocks
52-Week Change
87.46%vs all stocks
Market Capitalization
3.14BUSDvs all stocks (USD)
Enterprise Value
2.72BUSDvs all stocks (USD)
Forward P/E
-7.38xvs Biotechnology peers
Price to Sales (TTM)
26.84xvs Biotechnology peers
Price to Book (MRQ)
6.83xvs Biotechnology peers
Enterprise to Revenue
23.21xvs Biotechnology peers
Enterprise to EBITDA
-5.71xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-234.15%vs Biotechnology peers
Return on Assets (TTM)
-30.39%vs Biotechnology peers
Return on Equity (TTM)
-90.82%vs Biotechnology peers
Revenue (TTM)
117.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9820USDUpdated Sep 28, 2026Quarterly Revenue Growth
-74.40%vs Biotechnology peers
Gross Profit (TTM)
-380.00MUSDvs all stocks (USD)
EBITDA (TTM)
-476.00MUSDvs all stocks (USD)
Net Income (TTM)
-460.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-74.38%vs Biotechnology peers
Operating Cash Flow (TTM)
-474.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-270.62MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
247.00MUSDFY2025 · Dec 31, 2025Operating Income
-386.00MUSDvs all stocks (USD)
Pre-tax Income
-353.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-353.00MUSDFY2025 · Dec 31, 2025EBIT
-345.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-335.00MUSDFY2025 · Dec 31, 2025Research & Development
523.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
110.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
41.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.00MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-353.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-469.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
-471.00MUSDDerived from operating cash flow minus capital expenditure. This filing charges 10M of depreciation against 2M of capital expenditure, and its own free-cash-flow line reads -484M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.00MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
7.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-353.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
60.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
8.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
9.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
24.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-227.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.08BUSDFY2025 · Dec 31, 2025Sale of Investments
1.14BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
66.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
49.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
478.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
127.00MSharesUpdated Sep 28, 2026Float Shares
90.53MSharesUpdated Sep 28, 2026Shares Short
13.81MSharesUpdated Sep 28, 2026Short Ratio
9.41daysvs all stocks
Short % of Shares Outstanding
17.71%vs all stocks
% Held by Insiders
28.80%vs all stocks
% Held by Institutions
74.78%vs all stocks
Total Cash (MRQ)
702.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.51USDUpdated Sep 28, 2026Total Debt (MRQ)
238.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5129xvs Biotechnology peers
Current Ratio (MRQ)
3.82xvs Biotechnology peers
Book Value per Share (MRQ)
3.65USDUpdated Sep 28, 2026Total Assets
1.14BUSDvs all stocks (USD)
Total Current Assets
1.01BUSDFY2025 · Dec 31, 2025Total Liabilities
508.00MUSDFY2025 · Dec 31, 2025Total Non-current Assets
132.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
277.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
231.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
222.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
759.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.00MUSDFY2025 · Dec 31, 2025Accounts Payable
42.00MUSDFY2025 · Dec 31, 2025Short-term Debt
13.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
35.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
18.00MUSDFY2025 · Dec 31, 2025Long-term Debt
99.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
135.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.12BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.49BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
631.00MUSDvs all stocks (USD)
52-Week Low
12.87USDUpdated Sep 28, 202652-Week High
31.73USDUpdated Sep 28, 202652-Week Change
87.46%vs all stocks
Beta
0.8120xvs all stocks
50-Day MA
28.17USDUpdated Sep 28, 2026200-Day MA
24.74USDUpdated Sep 28, 2026Avg 10-Day Volume
1.87MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.57MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.94USDUpdated Sep 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 26.84Revenue Growth YoY: -0.74
Financial Health
Altman Z-Score 1.92: grey zoneSignificant
Altman Z-Score: 1.92
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$270.62M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -270,624,992Global P5: -204,451,341.808
Market cap is $3.14B, above the global median of $1.2BNotable
Market cap (USD): 3,140,555,855Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule